Dr. Mark Sleeman

Biography

Mark Sleeman has a combined background in neurobiology, endocrinology, and biochemistry, and has published extensively in high-impact journals such as PNAS, Cell Metabolism, and Nature Medicine. He is a leading figure in metabolic research, challenging established theories in insulin signaling and diabetes, particularly concerning the roles of ChREBP, SHIP2, and Trb3. His groundbreaking work has expanded the understanding of gut peptide ghrelin. Throughout his research career, he has focused on the interplay between insulin resistance and obesity, examining the molecular mechanisms that regulate food intake and body weight. Sleeman's innovative studies use a combination of mouse and human genomic approaches alongside gene expression analysis and physiological studies to elucidate the primary mechanisms of action of gut hormones. He has led scientific teams in world-class biotechnology companies, demonstrating exceptional leadership while driving therapeutic development. Sleeman holds a Ph.D. from Monash University, Australia, and has contributed to numerous professional societies and journals. He is recognized for his contributions to understanding the complex relationships between circulating hormones and metabolic regulation.

Research Interests